MedTrace Logo

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion

NCT05532735 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-12-11

No results posted yet for this study

Summary

Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.

Conditions

  • Retinal Vein Occlusion

Interventions

BIOLOGICAL

ANXV

ANXV (Human recombinant Annexin A5 protein)

Sponsors & Collaborators

  • InFocus Clinical Research

    collaborator INDUSTRY

  • Annexin Pharmaceuticals AB

    lead INDUSTRY

Principal Investigators

  • Anna Frostegård · Annexin Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-24
Primary Completion
2024-07-17
Completion
2024-11-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05532735 on ClinicalTrials.gov